RP G28

Drug Profile

RP G28

Alternative Names: RP-G28

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Ritter Pharmaceuticals
  • Developer Ritter Pharmaceuticals; University of British Columbia
  • Class Digestion aids; Oligosaccharides
  • Mechanism of Action Bacterial growth stimulants; Carbohydrate metabolism stimulants; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Lactose intolerance
  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 27 Feb 2017 Ritter Pharmaceuticals has patent protection for galacto-oligosaccharide pharmaceutical compositions in Italy and China (Ritter Pharmaceuticals Annual report 2016)
  • 27 Feb 2017 Ritter Pharmaceuticals initiates Long-term extension study for Lactose intolerance in USA before February 2017
  • 27 Feb 2017 Ritter Pharmaceuticals plans a phase III trial for Lactose intolerance in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top